We are live on ! Find out more
PBPIA

Pivotal bioVenture Partners Investment Advisor Portfolio holdings

AUM $280M
1-Year Est. Return 181.4%
This Fund
S&P 500
This Quarter Est. Return
+57.37%
1 Year Est. Return
+181.4%
3 Year Est. Return
+730.97%
5 Year Est. Return
+1,157.4%
10 Year Est. Return
–
AUM
$156M
AUM Growth
-$239M
Cap. Flow
-$281M
Cap. Flow %
-180.37%
Top 10 Hldgs %
99.53%
Holding
13
New
–
Increased
1
Reduced
2
Closed
2

Top Buys

Rank Stock Value
1
ARQT icon
Arcutis Biotherapeutics
ARQT
+$881K

Top Sells

Rank Stock Value
1
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$252M
2
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
+$13.8M
3
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
+$11.9M
4
OCS icon
Oculis Holding
OCS
+$3.51M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PCVX icon
1
Vaxcyte
PCVX
$8.9B
$54.2M 34.82%
793,036
– –
INZY
2
DELISTED
Inozyme Pharma
INZY
$34.4M 22.13%
4,494,851
– –
ARQT icon
3
Arcutis Biotherapeutics
ARQT
$3.28B
$20.1M 12.92%
2,028,008
+117,999
+6% +$881K
OCS icon
4
Oculis Holding
OCS
$722M
$19.2M 12.36%
1,595,918
-292,870
-16% -$3.51M
FUSN
5
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$12M 7.72%
563,385
-997,597
-64% -$11.9M
RLYB icon
6
Rallybio
RLYB
$87.9M
$4.45M 2.86%
300,581
– –
EXAI
7
DELISTED
Exscientia Plc American Depositary Shares
EXAI
$4.41M 2.83%
770,500
– –
BOLT icon
8
Bolt Biotherapeutics
BOLT
$6.49M
$2.65M 1.7%
94,573
– –
VIGL
9
DELISTED
Vigil Neuroscience
VIGL
$1.91M 1.23%
560,595
– –
IOBT
10
DELISTED
IO Biotech
IOBT
$1.5M 0.96%
864,197
– –
ALGS icon
11
Aligos Therapeutics
ALGS
$46.5M
$728K 0.47%
29,729
– –
KRTX
12
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
– –
-797,008
Closed -$252M
GRCL
13
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
– –
-1,375,000
Closed -$13.8M

Similar funds

HCM
Hall Capital Management Barrington, Rhode Island $280M AUM 14.82% 1-Year Est. Return
OFCM
One Fin Capital Management San Francisco, California $280M AUM 49.87% 1-Year Est. Return
NCM
NCM Capital Management Ramsey, New Jersey $279M AUM 26.47% 1-Year Est. Return
CCC
Compass Capital Corp Braintree, Massachusetts $279M AUM 28.36% 1-Year Est. Return
PHC
Panoramic Hills Capital Road Town $280M AUM
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
SL
SOF Ltd George Town, Cayman Islands $279M AUM 6.12% 1-Year Est. Return
CC
Checkpoint Capital San Francisco, California $279M AUM 45.74% 1-Year Est. Return

Pivotal bioVenture Partners Investment Advisor's Q1 2024 Portfolio in Review

As of Q1 2024, Pivotal bioVenture Partners Investment Advisor held 13 positions worth $156M, down 61% from $394M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Pivotal bioVenture Partners Investment Advisor withdrew a net $281M in Q1 2024, closing 2 positions and reducing 2 holdings. Its most notable exit was Karuna Therapeutics, Inc. Common Stock, an estimated $252M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Pivotal bioVenture Partners Investment Advisor added an estimated $881K to Arcutis Biotherapeutics.

  • Pivotal bioVenture Partners Investment Advisor added most to Arcutis Biotherapeutics in Q1 2024, an estimated $881K increase.
  • Pivotal bioVenture Partners Investment Advisor's biggest Q1 2024 reduction was Fusion Pharmaceuticals Inc. Common Shares, cutting an estimated $11.9M.
  • Pivotal bioVenture Partners Investment Advisor fully exited Karuna Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $252M.
  • Pivotal bioVenture Partners Investment Advisor's ten largest holdings make up 100% of its $156M portfolio in Q1 2024.
  • Pivotal bioVenture Partners Investment Advisor opened 0 new positions and closed 2 in Q1 2024.
  • Pivotal bioVenture Partners Investment Advisor's portfolio value fell 61% quarter-over-quarter to $156M.

Based on Pivotal bioVenture Partners Investment Advisor's 13F filing for Q1 2024, filed 14 May 2024.